What Happens If Atrial Fibrillation Goes Untreated?

Untreated atrial fibrillation raises the risk of stroke roughly fivefold, can gradually weaken the heart muscle, and is linked to higher rates of dementia, kidney decline, and premature death. The condition also tends to worsen on its own: what starts as occasional episodes often progresses to a permanent, harder-to-treat rhythm disturbance. These consequences unfold over months to years, which is part of what makes AF so deceptive. Many people feel only mild symptoms, or none at all, while damage accumulates quietly in the background.

Stroke Is the Headline Risk

The single most feared consequence of untreated AF is stroke. When the upper chambers of the heart quiver instead of contracting properly, blood pools and moves sluggishly, especially in a small pouch called the left atrial appendage. That stagnant blood can form clots, which then travel to the brain and block an artery. Most clot-related strokes in people with AF originate in this appendage.¹ The degree of risk depends on other factors like age, high blood pressure, and diabetes, but overall AF is tied to about a fivefold increase in stroke risk compared to people with a normal heart rhythm.²

Scarring in the atrial wall, known as fibrosis, makes the problem worse. Patients with more fibrosis have more areas where blood flow is slow and turbulent, creating additional sites where clots can form.² This fibrosis tends to worsen the longer AF persists, which is one reason early treatment matters.

AF-Related Strokes Are Often More Severe

Not all strokes are equal. The ones caused by AF tend to be bigger and more devastating than strokes from other causes, because the clots formed in the heart are often large. In large national datasets, people with AF are significantly more likely to suffer very severe strokes than people without AF. One contemporary nationwide study found that about 14% of stroke patients with AF had very severe strokes, compared with roughly 8% of those without AF.³ AF-related strokes also carry about twice the mortality rate of strokes from other causes.⁴

When researchers looked closely at why stroke outcomes were worse in AF patients, much of the difference came down to stroke severity itself: AF produces bigger clots, which cause bigger strokes, which cause more disability and death. After accounting for the size of the stroke, the independent contribution of AF to mortality shrank considerably, though it did not disappear entirely.⁵ The practical takeaway is clear: the strokes themselves are the main killer, and preventing them with anticoagulant medication is the single highest-value intervention for most AF patients.

The Rhythm Gets Worse Over Time

AF is a progressive condition. It typically begins as paroxysmal, meaning it comes and goes in episodes. Over time, many patients progress to persistent AF (episodes that last longer and no longer stop on their own) and eventually permanent AF (a continuous irregular rhythm that clinicians and the patient decide not to try reversing). In one study tracking patients over an average of nearly five years, about a third of those who started with paroxysmal AF progressed to persistent or permanent forms.⁶ A systematic review found that within the first year, somewhere between 10% and 20% of paroxysmal patients progressed, climbing to 50% to 77% after a dozen years of follow-up.⁷

This progression happens because AF itself changes the heart’s tissue. The electrical misfiring causes structural remodeling: atrial walls stretch, scar tissue accumulates, and the electrical wiring gets increasingly disorganized.⁸ In cardiology, this is sometimes described as “AF begets AF.” The longer the heart stays in fibrillation, the harder it becomes to coax it back to a normal rhythm. The factors that speed up progression are the ones you might expect: obesity, heart failure, valve disease, high blood pressure, diabetes, and an enlarged left atrium.⁹ On the flip side, regular physical activity and catheter ablation procedures are both associated with slower progression.⁹

Heart Failure and a Weakened Heart

AF and heart failure have a deeply tangled relationship. Each condition raises the risk of the other, and when they coexist, outcomes get considerably worse. The fast and irregular ventricular rates that come with uncontrolled AF force the heart to work harder continuously, and over weeks to months that extra workload can weaken the muscle. This is sometimes called tachycardia-mediated cardiomyopathy: the heart weakens not because of blocked arteries or a viral infection, but simply because it has been beating too fast for too long.

In some patients, heart failure is the first sign that AF has been going on in the background. One study comparing patients with new heart failure found that those whose heart failure appeared alongside or after an AF diagnosis tended to be older, more likely to be male, and to carry a higher burden of other health conditions.¹⁰ The encouraging part of this picture is that if the rapid heart rate was the primary driver of the weak heart, restoring a normal rhythm or simply slowing the rate can partially or fully reverse the damage. But the longer the heart has been under strain, the less likely full recovery becomes.

Higher Mortality Across the Board

Beyond stroke and heart failure, untreated AF is independently linked to dying sooner from a range of causes. Data from the Framingham Heart Study, one of the longest-running heart studies in the world, found that mortality rates were roughly 50% higher in men and 90% higher in women who developed AF compared to those who did not. Similar patterns showed up in other large cohorts, including the Women’s Health Study, where mortality rates more than doubled among women with AF, and the Atherosclerosis Risk in Communities Study, which reported a doubling of mortality in people diagnosed with AF regardless of race.¹¹

There is a reasonable debate about how much of this excess mortality is “caused by AF” versus caused by the conditions that travel with it: hypertension, diabetes, obesity, and lung disease. The answer is probably both. AF clearly worsens outcomes through stroke and heart failure, but the associated conditions pile on additional risk. Among patients with permanent AF, one study found an all-cause mortality rate of nearly 40% during follow-up, compared with under 9% in those whose AF had not become permanent.¹²

Cognitive Decline and Dementia

A growing body of evidence connects AF to a higher risk of cognitive impairment and dementia, even in people who never have a recognized stroke. Community-based studies consistently show that people with AF experience faster mental decline over time.¹³ Part of this is explained by the increased chance of having a clinically obvious stroke, but researchers believe other mechanisms are at play. AF may cause tiny, undetected strokes (so-called silent brain infarcts), microbleeds, and chronic reductions in blood flow to the brain.¹⁴

The association between AF and dementia appears to hold up even after researchers account for the strokes they can see, which suggests that the rhythm disturbance itself, or the inflammation and blood-flow changes it produces, may be quietly damaging the brain over years.¹⁵ Whether anticoagulation or rhythm-control treatments can slow this cognitive decline is an active area of research, and there are no definitive answers yet. But the link between untreated AF and brain health is one that many people are not aware of, and it strengthens the case for not ignoring the condition.

Silent AF and Hidden Strokes

One of the most insidious aspects of AF is that many episodes produce no symptoms at all. Among patients with a documented history of symptomatic AF, asymptomatic episodes are common and likely underestimated.¹⁶ Patients with implanted cardiac devices reveal the scope of the problem: data from these monitors show that silent AF is widespread, and that even brief episodes may increase the risk of blood clots. The threshold at which stroke risk becomes clinically worrying might be as short as several minutes to several hours of AF.¹⁷

Silent strokes compound the issue. People with AF have a higher prevalence of brain infarcts that show up on imaging but never caused noticeable symptoms.¹⁸ Over time these silent infarcts may accumulate and contribute to the cognitive decline discussed above. The combination of a rhythm disorder that you cannot feel and strokes that you cannot detect makes AF uniquely dangerous when left unmonitored.

How Much AF Is Enough to Worry About?

One question that physicians and patients both wrestle with is how long an episode of AF needs to last before the stroke risk becomes meaningful. Research using data from implanted cardiac devices has sharpened the picture. Episodes of subclinical AF lasting more than 24 hours were associated with more than a threefold increase in the risk of stroke or systemic embolism. Shorter episodes, between six minutes and 24 hours, did not reach statistical significance for stroke risk on their own.¹⁹

But duration does not tell the whole story. A person’s underlying stroke risk profile matters enormously. In a study of over 21,000 patients with implanted devices, people with low baseline risk scores had low stroke rates regardless of how much AF their device recorded. Those with higher risk scores crossed a clinically actionable stroke threshold with as little as six minutes of AF.²⁰ In other words, a brief episode of AF in an otherwise healthy 50-year-old is very different from a brief episode in a 75-year-old with high blood pressure and diabetes.

The Heart Can Starve Itself of Oxygen

A less widely discussed consequence of uncontrolled AF is its potential to provoke episodes of reduced blood flow to the heart muscle itself. When the ventricles beat rapidly during AF, two things happen at once: the heart demands more oxygen because it is working harder, and the time available for coronary blood flow shrinks because the resting phase between beats gets shorter.²¹ In people who already have some degree of coronary artery narrowing, this mismatch can tip the balance into actual ischemia, producing chest pain or, in some cases, heart damage even without a full-blown heart attack.²² Rate control, whether achieved with medication or by restoring a normal rhythm, directly addresses this problem.

Women Face a Different Risk Profile

The consequences of untreated AF are not identical for men and women. Women with AF tend to have more extensive scarring of the left atrium and heightened sensitivity to clot-forming signals, especially after menopause.²³ In one large study of patients not taking warfarin, women had annual blood-clot rates of about 3.5%, compared with about 1.8% for men.²⁴ Despite this higher baseline risk, women are frequently under-prescribed anticoagulant therapy compared with men, a gap that researchers have flagged as a persistent equity problem.²³

Mortality data tell a parallel story. In the Framingham and Renfrew/Paisley cohorts, the excess mortality associated with AF was proportionally larger in women than in men.¹¹ On the treatment side, though, when women do receive anticoagulation, the benefit is at least as large as it is for men, which makes the prescribing gap all the more frustrating.

Why Early Treatment Makes a Difference

Given that AF remodels the heart and becomes harder to treat the longer it persists, timing matters. A large real-world study compared patients who underwent catheter ablation within a year of their AF diagnosis to those who waited longer. Those treated within the first year had significantly lower odds of AF recurrence at both three and five years. By the five-year mark, early ablation was also associated with reductions in secondary outcomes including hospitalizations.²⁵ The same systematic review that documented high long-term progression rates in untreated patients found that catheter ablation dropped the rate of progression to persistent AF to roughly 2.4% to 2.7% over five years, a dramatic reduction compared with the general population numbers.⁷

This does not mean every patient needs an immediate procedure. For recent-onset symptomatic AF, a wait-and-see approach in which the heart is given a chance to return to normal rhythm on its own was shown to be comparable to immediate cardioversion for restoring sinus rhythm at four weeks, with roughly 91% of the delayed group back in normal rhythm by that time.²⁶ The key distinction is between a brief, watched delay and indefinite neglect. Leaving AF untreated for months or years is where the damage accumulates.

AF and the Kidneys

A less familiar consequence of AF is its effect on kidney function. The same sluggish blood flow and inflammatory state that promote clots in the heart can also affect how clots form and dissolve throughout the body, with downstream effects on the kidneys. A study tracking kidney function over time in AF patients found that the estimated filtration rate declined by a median of about 8 points during follow-up, corresponding to roughly 1.8 units per year. Changes in clot structure were independently tied to this decline, along with age, baseline kidney function, and blood pressure.²⁷ The relationship works in both directions: worsening kidneys raise the risk of bleeding complications and make anticoagulant dosing trickier, which compounds the challenge of managing AF over the long term.

The Financial Toll

Untreated or poorly managed AF also carries a significant economic burden. A recent analysis of privately insured employees in the U.S. found that people with AF incurred about $11,400 more in annual medical costs than matched individuals without AF, after adjusting for other conditions. The total adjusted annual medical cost for someone with AF averaged roughly $19,500, compared with about $8,200 for someone without. On top of that, AF patients had more emergency department visits, more inpatient stays, more outpatient visits, and more prescriptions filled each year, along with nearly an extra day of sick leave and about three extra short-term disability days annually.²⁸ These numbers reflect the burden of the condition even when treatment is available, and they would presumably be worse if strokes and heart failure episodes went unpreventable for lack of treatment.

Smartwatches and the Detection Gap

One reason AF so often goes untreated is that it goes undetected. A person whose AF is intermittent and symptom-free may never know they have it unless a device happens to catch it. Consumer smartwatches have entered this space with surprising accuracy. A meta-analysis of 26 studies covering more than 17,000 patients found that smartwatches as a category achieved about 95% sensitivity and 97% specificity for detecting AF. Individual brands performed well, with the Apple Watch at roughly 94% sensitivity and 97% specificity, and Samsung devices at about 97% and 96%.²⁹ These numbers sound impressive, and for picking up AF in people who would otherwise never be checked, wearables offer genuine value. They are not, however, a replacement for clinical monitoring. A smartwatch notification should always prompt a proper medical workup with a standard ECG or longer-term monitor, both to confirm the rhythm and to figure out what to do about it.

The autonomic nervous system adds another layer of complexity to the AF picture. Sympathetic and vagal nerve activity can both trigger and sustain AF episodes, and their influence is amplified by common AF companions like obesity, high blood pressure, and sleep apnea.³⁰ This means that some lifestyle factors, especially sleep quality, weight management, and stress reduction, may affect not just the risk of developing AF but also how often it fires and how quickly it progresses. It is one of the reasons that AF management increasingly looks beyond pills and procedures to address the broader metabolic and neurological environment in which the rhythm disturbance lives.

1
PubMed. Stroke risk evaluation for patients with atrial fibrillation: Insights from left atrial appendage with fluid-structure interaction analysis
2
PubMed Central. Presence of Left Atrial Fibrosis May Contribute to Aberrant Hemodynamics and Increased Risk of Stroke in Atrial Fibrillation Patients
3
PubMed Central. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation
4
European Cardiology. Stroke Prevention in Atrial Fibrillation – The Unmet Need and Morbidity Burden
5
PubMed. Association of atrial fibrillation with mortality and disability after ischemic stroke
6
PubMed Central. Evolution of Paroxysmal Atrial Fibrillation to Persistent or Permanent Atrial Fibrillation: Predictors of Progression
7
JACC: Clinical Electrophysiology. A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation: Shedding New Light on the Effects of Catheter Ablation
8
PubMed Central. The Progressive Nature of Atrial Fibrillation: A Rationale for Early Restoration and Maintenance of Sinus Rhythm
9
PubMed Central. Incidence and Predictors of Atrial Fibrillation Progression
10
PubMed Central. New-onset Heart Failure With Atrial Fibrillation: A Distinct Type of Cardiomyopathy?
11
PubMed Central. Mortality in atrial fibrillation. Is it changing?
12
Medical Science Monitor. Association of Permanent Atrial Fibrillation With Mortality and Heart Failure Progression in Low Thromboembolic Risk Patients
13
PubMed Central. Atrial Fibrillation, Cognitive Decline And Dementia
14
EP Europace. Does atrial fibrillation cause cognitive decline and dementia?
15
PubMed. Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration
16
PubMed. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide
17
PubMed. Silent atrial fibrillation as a stroke risk factor and anticoagulation indication
18
PubMed Central. Atrial fibrillation and silent stroke: links, risks, and challenges
19
European Heart Journal. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
20
PubMed. Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score
21
International Journal of Cardiology. Fatal attraction — A brief pathophysiology of the interaction between atrial fibrillation and myocardial ischemia
22
PubMed. Myocardial Ischemia due to Rapid Atrial Fibrillation Revealed Using the Instantaneous Wave-Free Ratio
23
PubMed Central. The Pathophysiology of Sex Differences in Stroke Risk and Prevention in Atrial Fibrillation: A Comprehensive Review
24
PubMed Central. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study
25
PubMed Central. Early vs delayed ablation for new-onset atrial fibrillation: 5-Year real-world data outcomes
26
PubMed. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation
27
PubMed. Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation
28
JAMA Network Open. Medical Costs and Productivity Losses of Atrial Fibrillation Among US Privately Insured Employees
29
PubMed Central. Accuracy of Smartwatches in the Detection of Atrial Fibrillation: A Systematic Review and Diagnostic Meta-Analysis
30
PubMed. Role of autonomic nervous system in atrial fibrillation